AstraZeneca PLC (AZN)vsCytek Biosciences Inc (CTKB)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
CTKB
Cytek Biosciences Inc
$4.56
+2.70%
HEALTHCARE · Cap: $565.62M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 29052% more annual revenue ($58.74B vs $201.49M). AZN leads profitability with a 17.4% profit margin vs -33.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
CTKB
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+51.2%
Fair Value
$8.94
Current Price
$4.56
$4.38 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Earnings expanding 73.5% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -18.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : CTKB
The strongest argument for CTKB centers on EPS Growth, Debt/Equity, Altman Z-Score.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : CTKB
The primary concerns for CTKB are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a value stock while CTKB is a turnaround play — different risk/reward profiles.
CTKB carries more volatility with a beta of 1.28 — expect wider price swings.
CTKB is growing revenue faster at 8.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 41/100), backed by strong 17.4% margins. CTKB offers better value entry with a 51.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Cytek Biosciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Cytek Biosciences Inc (CTKB) is a leading innovator in multi-parameter flow cytometry, delivering cutting-edge cell analysis solutions that are vital for advancements in the life sciences sector. Specializing in technologies that enhance cellular analyses, Cytek plays a significant role in research areas such as immunology, cancer diagnostics, and drug development. The company's commitment to innovation and exceptional customer service has established it as a key player in the biotechnology industry, effectively meeting the increasing demand for accurate and precise cell analysis tools. With a diverse product portfolio and a strong market presence, Cytek continues to push the boundaries of cell biology research, fostering breakthroughs that can transform healthcare outcomes.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?